Literature DB >> 27033542

Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism.

Giuseppe Viccica1, Filomena Cetani2, Edda Vignali2, Mario Miccoli1, Claudio Marcocci3,4.   

Abstract

The purpose of the study was to evaluate the relationship between serum 25(OH)D and the clinical phenotype in 215 consecutive Italian Caucasian women with sporadic primary hyperparathyroidism (PHPT) not taking vitamin D supplements. The study was performed at a single Italian tertiary center. PHPT-related manifestations, serum 25(OH)D, and other parameters of calcium metabolism and bone mineral density (BMD) by DXA were recorded. Serum 25(OH)D was negatively correlated with age (r = -0.18; P = 0.006), BMI (r = -0.20; P = 0.002), PTH (r = -0.21; P = 0.001), bone-specific alkaline phosphatase (BSAP) (r = -0.27; P < 0.001), and eGFR (r = -0.22; P = 0.01), and positively with serum creatinine and 1/3 distal radius BMD (R-BMD; r = 0.17; P = 0.015). In a multivariate regression analysis, serum 25(OH)D remained significantly correlated with age (r = -0.18; P = 0.005), BMI (r = -0.23; P = 0.049), serum PTH (r = -0.01; P = 0.023), BSAP (r = -0.01; P = 0.023) and eGFR (r = -0.09; P = 0.001), but not with R-BMD. Serum 25(OHD) was higher in patients with nephrolithiasis than in those without nephrolithiasis (18.5 ± 8.8 vs. 15.6 ± 8.0 ng/ml; P = 0.029), whereas no difference was found between fractured and unfractured patients (16.8 ± 9.3 vs. 16.0 ± 7.7; P = 0.663). There was a statistically significant inverse correlation between vitamin D status [defined by quartiles of measured values as well as commonly accepted cutoffs of serum 25(OH)D] and severity of the disease, as reflected by higher PTH and BSAP, but not by meeting the latest guidelines for parathyroidectomy. In conclusion, a low vitamin D status is associated with some features reflecting a more severe biochemical and clinical phenotype of PHPT in Italian women not taking vitamin D supplements.

Entities:  

Keywords:  25(OH)D; Fractures; Nephrolithiasis; PTH; Parathyroidectomy

Mesh:

Substances:

Year:  2016        PMID: 27033542     DOI: 10.1007/s12020-016-0931-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  41 in total

1.  Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai.

Authors:  Jian-Min Liu; Natalie E Cusano; Barbara C Silva; Lin Zhao; Xiao-Yan He; Bei Tao; Li-Hao Sun; Hong-Yan Zhao; Wen-Wei Fan; Megan E Romano; Guang Ning; John P Bilezikian
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

2.  Determinants of urolithiasis before and after parathyroidectomy in patients with primary hyperparathyroidism.

Authors:  Mohamed A Elkoushy; Alice X Yu; Roger Tabah; Richard J Payne; Alice Dragomir; Sero Andonian
Journal:  Urology       Date:  2014-04-02       Impact factor: 2.649

3.  Nephrolithiasis and bone involvement in primary hyperparathyroidism.

Authors:  S J Silverberg; E Shane; T P Jacobs; E S Siris; F Gartenberg; D Seldin; T L Clemens; J P Bilezikian
Journal:  Am J Med       Date:  1990-09       Impact factor: 4.965

Review 4.  Nephrolithiasis and renal calcifications in primary hyperparathyroidism.

Authors:  Lars Rejnmark; Peter Vestergaard; Leif Mosekilde
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

5.  Vitamin D status in primary hyperparathyroidism.

Authors:  Walid Saliba; Idit Lavi; Hedy S Rennert; Gad Rennert
Journal:  Eur J Intern Med       Date:  2011-08-12       Impact factor: 4.487

6.  Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency.

Authors:  Andrew Grey; Jenny Lucas; Anne Horne; Greg Gamble; James S Davidson; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2005-01-11       Impact factor: 5.958

7.  Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency.

Authors:  Todd D Beyer; Emery L Chen; Naris Nilubol; Richard A Prinz; Carmen C Solorzano
Journal:  J Surg Res       Date:  2007-07-25       Impact factor: 2.192

Review 8.  Asymptomatic primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Marcella D Walker; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

9.  Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians.

Authors:  Shweta Varshney; Sanjay Kumar Bhadada; Uma Nahar Saikia; Naresh Sachdeva; Arunanshu Behera; Ashutosh Kumar Arya; Sadhna Sharma; Anil Bhansali; Ambrish Mithal; Sudhaker D Rao
Journal:  Eur J Endocrinol       Date:  2013-06-07       Impact factor: 6.664

10.  Systematic review of primary hyperparathyroidism in India: the past, present, and the future trends.

Authors:  P V Pradeep; B Jayashree; Anjali Mishra; S K Mishra
Journal:  Int J Endocrinol       Date:  2011-05-26       Impact factor: 3.257

View more
  15 in total

1.  Occult urolithiasis in asymptomatic primary hyperparathyroidism.

Authors:  Yu-Kwang Donovan Tay; Minghao Liu; Leonardo Bandeira; Mariana Bucovsky; James A Lee; Shonni J Silverberg; Marcella D Walker
Journal:  Endocr Res       Date:  2018-02-05       Impact factor: 1.720

2.  Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?

Authors:  F Saponaro; F Cetani; L Mazoni; M Apicella; M Di Giulio; F Carlucci; M Scalese; E Pardi; S Borsari; J P Bilezikian; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-12-23       Impact factor: 4.256

Review 3.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

4.  Vitamin D and primary hyperparathyroidism: more insights into a complex relationship.

Authors:  Marcella D Walker; John P Bilezikian
Journal:  Endocrine       Date:  2016-11-17       Impact factor: 3.633

5.  Clinical profile of juvenile primary hyperparathyroidism: a prospective study.

Authors:  Federica Saponaro; Claudio Marcocci; Federica Cacciatore; Mario Miccoli; Elena Pardi; Simona Borsari; Gabriele Materazzi; Paolo Miccoli; Filomena Cetani
Journal:  Endocrine       Date:  2017-05-20       Impact factor: 3.633

Review 6.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

Review 7.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

8.  Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016.

Authors:  B Sun; B Guo; B Wu; J Kang; X Deng; Z Zhang; Y Fan
Journal:  Osteoporos Int       Date:  2017-12-03       Impact factor: 4.507

Review 9.  Parathyroidectomy: is vitamin D a player for a good outcome?

Authors:  M Carsote; D N Paduraru; A E Nica; A Valea
Journal:  J Med Life       Date:  2016 Oct-Dec

10.  A Comparison between Silent and Symptomatic Renal Stones in Primary Hyperparathyroidism.

Authors:  Raiz Ahmad Misgar; Ashish Sehgal; Shariq Rashid Masoodi; Arshad Iqbal Wani; Mir Iftikhar Bashir; Ajaz Ahmad Malik; Munir Ahmad Wani; Muzaffar Maqsood Wani; Imtiyaz Ahmad Wani
Journal:  Indian J Endocrinol Metab       Date:  2019 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.